<p>根據 Marketbeat Ratings 的報告，Globus Medical, Inc.（紐約證券交易所代碼：GMED - 獲取免費報告）的股票獲得了 14 家評級公司的平均推薦為 “適度買入”。六位投資分析師對該股票給予了持有推薦，八位分析師則對該公司發出了買入推薦。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為 93.1111 美元。</p>
<p>獲取 <strong>Globus Medical</strong> 的提醒：</p>
<p>幾家研究公司對 GMED 發表了評論。Zacks Research 在 12 月 9 日的研究報告中將 Globus Medical 的評級從 “強力買入” 下調至 “持有”。加拿大皇家銀行在 12 月 17 日的報告中將 Globus Medical 的目標價從 92.00 美元上調至 100.00 美元，並給予該公司 “跑贏大盤” 的評級。Truist Financial 在 11 月 18 日的研究報告中重申了 “買入” 評級，並將 Globus Medical 的目標價從 93.00 美元上調至 105.00 美元。華爾街 Zen 在 12 月 6 日的研究報告中將 Globus Medical 的評級從 “強力買入” 下調至 “買入”。最後，美國銀行在 11 月 7 日的報告中將 Globus Medical 的評級從 “中性” 上調至 “買入”，並將該公司的目標價從 65.00 美元上調至 91.00 美元。</p>
<p><strong>查看我們最新的 GMED 股票分析</strong></p>
<h2>Globus Medical 股票表現</h2>
<p>紐約證券交易所：GMED 週五開盤價為 88.47 美元。該公司的 50 日移動平均線為 80.19 美元，200 日移動平均線為 65.75 美元。該公司的市值為 118.4 億美元，市盈率為 28.54，PEG 比率為 1.63，貝塔值為 1.07。Globus Medical 的年內最低價為 51.79 美元，年內最高價為 94.93 美元。</p>
<p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最近在 11 月 6 日發佈了季度財報。這家醫療設備公司報告的每股收益（EPS）為 1.18 美元，超出市場共識預期的 0.79 美元，超出幅度為 0.39 美元。該季度的營業收入為 7.6905 億美元，而分析師預期為 7.3458 億美元。Globus Medical 的股本回報率為 11.52%，淨利潤率為 15.30%。該公司的季度收入同比增長 22.9%。在去年同期，該公司每股收益為 0.83 美元。Globus Medical 已將其 2025 財年的指導目標設定為 3.750-3.85 美元每股。作為一個整體，股票研究分析師預測 Globus Medical 在當前財年將發佈 3.44 美元的每股收益。</p>
<h2>Globus Medical 的內部交易</h2>
<p>在相關消息中，董事 David D. Davidar 在 11 月 12 日的交易中出售了 25,000 股公司的股票。該股票以 86.00 美元的平均價格出售，總價值為 2,150,000.00 美元。交易完成後，該董事持有 516,275 股公司的股票，價值約為 44,399,650 美元。這代表其持股比例減少了 4.62%。該交易已在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。此外，董事 Ann D. Rhoads 在 11 月 7 日的交易中出售了 8,000 股公司的股票。該股票以 81.00 美元的平均價格出售，總價值為 648,000.00 美元。交易完成後，該董事直接持有 17,384 股公司的股票，價值約為 1,408,104 美元。該交易使其持股比例減少了 31.52%。該銷售的披露信息可在 SEC 文件中找到。內部人士在上個季度出售了價值 7,419,030 美元的 86,042 股公司股票。公司內部人士持有公司股票的 18.51%。</p>
<h2>機構投資者對 Globus Medical 的看法</h2>
<p>一些機構投資者最近增加或減少了對該股票的持股。Advisory Services Network LLC 在第三季度新購入了價值約 26,000 美元的 Globus Medical 股票。EverSource Wealth Advisors LLC 在第二季度將其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 現在擁有 462 股該醫療設備公司的股票，價值 27,000 美元，此前在上個季度又購買了 197 股。Advisors Asset Management Inc.在第二季度新購入了價值約 28,000 美元的 Globus Medical 股票。First Horizon Corp 在第三季度新購入了價值約 31,000 美元的 Globus Medical 股票。最後，Parallel Advisors LLC 在第三季度將其在 Globus Medical 的持股增加了 45.1%。Parallel Advisors LLC 現在擁有 557 股該醫療設備公司的股票，價值 32,000 美元，此前在上個季度又購買了 173 股。機構投資者和對沖基金持有公司 95.16% 的股票。</p>
<h2>關於 Globus Medical</h2>
<p>（獲取免費報告）</p>
<p>Globus Medical, Inc.（紐約證券交易所代碼：GMED）是一家領先的醫療設備公司，專注於脊柱和骨科應用的肌肉骨骼解決方案。該公司於 2003 年由 David C. Paul 創立，總部位於賓夕法尼亞州 Audubon，開發、製造和銷售旨在治療脊柱疾病和促進骨癒合的植入設備和外科器械。其產品組合涵蓋了用於微創和開放手術的解決方案，包括椎間融合設備、椎弓根螺釘系統和用於增強融合效果的生物製劑。</p>
<p>除了其核心脊柱業務外，Globus Medical 還擴展到機器人和導航系統，以支持手術室的精確性和效率。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比 Globus Medical 更好</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>[緊急！] SpaceX 即將上市！- IPO 前的行動</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>華盛頓為戰爭做準備</li>
<li>距離崩盤一個月</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
<p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Globus Medical 並不在名單上。</p>
<p>雖然 Globus Medical 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Globus醫療

<p>Globus Medical, Inc.（紐約證券交易所代碼：GMED）獲得了 14 家券商的平均 “適度買入” 評級，12 個月目標價為 93.11 美元。分析師發佈了 6 個持有和 8 個買入的建議。最近的變化包括 Zacks Research 將評級下調至 “持有”，加拿大皇家銀行將目標價上調至 100 美元。該公司報告了強勁的季度收益，超出預期，每股收益為 1.18 美元，收入為 7.6905 億美元。內部交易包括董事的重大股票出售</p>

<p>Shares of Globus Medical, Inc. (NYSE:GMED - Get Free Report) have earned an average recommendation of &#34;Moderate Buy&#34; from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $93.1111.</p>
<div class="lb-trans"><p>根據 Marketbeat Ratings 的報告，Globus Medical, Inc.（紐約證券交易所代碼：GMED - 獲取免費報告）的股票獲得了 14 家評級公司的平均推薦為 “適度買入”。六位投資分析師對該股票給予了持有推薦，八位分析師則對該公司發出了買入推薦。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為 93.1111 美元。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Globus Medical</strong> 的提醒：</p>
</div><p>Several research firms have commented on GMED. Zacks Research lowered Globus Medical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, December 9th. Royal Bank Of Canada lifted their target price on shares of Globus Medical from $92.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, December 17th. Truist Financial reiterated a &#34;buy&#34; rating and issued a $105.00 target price (up from $93.00) on shares of Globus Medical in a research note on Tuesday, November 18th. Wall Street Zen lowered shares of Globus Medical from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, December 6th. Finally, Bank of America raised shares of Globus Medical from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price objective for the company from $65.00 to $91.00 in a report on Friday, November 7th.</p>
<div class="lb-trans"><p>幾家研究公司對 GMED 發表了評論。Zacks Research 在 12 月 9 日的研究報告中將 Globus Medical 的評級從 “強力買入” 下調至 “持有”。加拿大皇家銀行在 12 月 17 日的報告中將 Globus Medical 的目標價從 92.00 美元上調至 100.00 美元，並給予該公司 “跑贏大盤” 的評級。Truist Financial 在 11 月 18 日的研究報告中重申了 “買入” 評級，並將 Globus Medical 的目標價從 93.00 美元上調至 105.00 美元。華爾街 Zen 在 12 月 6 日的研究報告中將 Globus Medical 的評級從 “強力買入” 下調至 “買入”。最後，美國銀行在 11 月 7 日的報告中將 Globus Medical 的評級從 “中性” 上調至 “買入”，並將該公司的目標價從 65.00 美元上調至 91.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on GMED</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 GMED 股票分析</strong></p>
</div><h2>Globus Medical Stock Performance</h2>
<div class="lb-trans"><h2>Globus Medical 股票表現</h2>
</div><p>NYSE:GMED opened at $88.47 on Friday. The firm's fifty day moving average is $80.19 and its two-hundred day moving average is $65.75. The firm has a market cap of $11.84 billion, a price-to-earnings ratio of 28.54, a PEG ratio of 1.63 and a beta of 1.07. Globus Medical has a one year low of $51.79 and a one year high of $94.93.</p>
<div class="lb-trans"><p>紐約證券交易所：GMED 週五開盤價為 88.47 美元。該公司的 50 日移動平均線為 80.19 美元，200 日移動平均線為 65.75 美元。該公司的市值為 118.4 億美元，市盈率為 28.54，PEG 比率為 1.63，貝塔值為 1.07。Globus Medical 的年內最低價為 51.79 美元，年內最高價為 94.93 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.39. The business had revenue of $769.05 million during the quarter, compared to analysts' expectations of $734.58 million. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The company's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.83 EPS. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, equities research analysts predict that Globus Medical will post 3.44 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最近在 11 月 6 日發佈了季度財報。這家醫療設備公司報告的每股收益（EPS）為 1.18 美元，超出市場共識預期的 0.79 美元，超出幅度為 0.39 美元。該季度的營業收入為 7.6905 億美元，而分析師預期為 7.3458 億美元。Globus Medical 的股本回報率為 11.52%，淨利潤率為 15.30%。該公司的季度收入同比增長 22.9%。在去年同期，該公司每股收益為 0.83 美元。Globus Medical 已將其 2025 財年的指導目標設定為 3.750-3.85 美元每股。作為一個整體，股票研究分析師預測 Globus Medical 在當前財年將發佈 3.44 美元的每股收益。</p>
</div><h2>Insider Transactions at Globus Medical</h2>
<div class="lb-trans"><h2>Globus Medical 的內部交易</h2>
</div><p>In related news, Director David D. Davidar sold 25,000 shares of the company's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $86.00, for a total value of $2,150,000.00. Following the completion of the transaction, the director owned 516,275 shares of the company's stock, valued at approximately $44,399,650. This represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ann D. Rhoads sold 8,000 shares of the firm's stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $81.00, for a total value of $648,000.00. Following the completion of the sale, the director directly owned 17,384 shares in the company, valued at approximately $1,408,104. The trade was a 31.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 86,042 shares of company stock worth $7,419,030 over the last quarter. Company insiders own 18.51% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 David D. Davidar 在 11 月 12 日的交易中出售了 25,000 股公司的股票。該股票以 86.00 美元的平均價格出售，總價值為 2,150,000.00 美元。交易完成後，該董事持有 516,275 股公司的股票，價值約為 44,399,650 美元。這代表其持股比例減少了 4.62%。該交易已在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。此外，董事 Ann D. Rhoads 在 11 月 7 日的交易中出售了 8,000 股公司的股票。該股票以 81.00 美元的平均價格出售，總價值為 648,000.00 美元。交易完成後，該董事直接持有 17,384 股公司的股票，價值約為 1,408,104 美元。該交易使其持股比例減少了 31.52%。該銷售的披露信息可在 SEC 文件中找到。內部人士在上個季度出售了價值 7,419,030 美元的 86,042 股公司股票。公司內部人士持有公司股票的 18.51%。</p>
</div><h2>Institutional Investors Weigh In On Globus Medical</h2>
<div class="lb-trans"><h2>機構投資者對 Globus Medical 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in shares of Globus Medical in the third quarter valued at about $26,000. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Globus Medical in the 2nd quarter valued at about $28,000. First Horizon Corp acquired a new stake in Globus Medical in the 3rd quarter worth about $31,000. Finally, Parallel Advisors LLC increased its stake in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock worth $32,000 after buying an additional 173 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對該股票的持股。Advisory Services Network LLC 在第三季度新購入了價值約 26,000 美元的 Globus Medical 股票。EverSource Wealth Advisors LLC 在第二季度將其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 現在擁有 462 股該醫療設備公司的股票，價值 27,000 美元，此前在上個季度又購買了 197 股。Advisors Asset Management Inc.在第二季度新購入了價值約 28,000 美元的 Globus Medical 股票。First Horizon Corp 在第三季度新購入了價值約 31,000 美元的 Globus Medical 股票。最後，Parallel Advisors LLC 在第三季度將其在 Globus Medical 的持股增加了 45.1%。Parallel Advisors LLC 現在擁有 557 股該醫療設備公司的股票，價值 32,000 美元，此前在上個季度又購買了 173 股。機構投資者和對沖基金持有公司 95.16% 的股票。</p>
</div><h2>About Globus Medical</h2>
<div class="lb-trans"><h2>關於 Globus Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.</p>
<div class="lb-trans"><p>Globus Medical, Inc.（紐約證券交易所代碼：GMED）是一家領先的醫療設備公司，專注於脊柱和骨科應用的肌肉骨骼解決方案。該公司於 2003 年由 David C. Paul 創立，總部位於賓夕法尼亞州 Audubon，開發、製造和銷售旨在治療脊柱疾病和促進骨癒合的植入設備和外科器械。其產品組合涵蓋了用於微創和開放手術的解決方案，包括椎間融合設備、椎弓根螺釘系統和用於增強融合效果的生物製劑。</p>
</div><p>In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.</p>
<div class="lb-trans"><p>除了其核心脊柱業務外，Globus Medical 還擴展到機器人和導航系統，以支持手術室的精確性和效率。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>[URGENT!] SpaceX Going Public! – Pre-IPO Action</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Washington prepares for war</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Globus Medical 更好</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>[緊急！] SpaceX 即將上市！- IPO 前的行動</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>華盛頓為戰爭做準備</li>
<li>距離崩盤一個月</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Globus Medical 並不在名單上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Globus Medical 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Globus 醫療公司（NYSE:GMED）被券商給予平均評級為 “適度買入”